Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

BackgroundBruton tyrosine kinase inhibitors (BTKis) interrupt B-cell receptor signaling and thereby could potentially reactivate hepatitis B virus (HBV). However, data about the risk for HBV reactivation (HBVr) of BTKis in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) patients are...

Full description

Bibliographic Details
Main Authors: Ying Ni, Lixia Gao, Yan Lu, Shiguang Ye, Lili Zhou, Wenbin Qian, Aibin Liang, Ping Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
HBV reactivation
diffuse large B-cell lymphoma
Bruton tyrosine kinase inhibitor
resolved HBV infection
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.982346/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.982346/full

Similar Items